The domestic CAR-T price is released for the first time!

On October 26, the Guangdong Provincial Pharmaceutical Exchange Center announced the new products (third batch) newly approved for listing on the third-party drug electronic trading platform of Guangdong Province and the notice of the prices to be listed on the Internet, and disclosed the prices of 6 new drugs

Since September this year, the Guangdong Pharmaceutical Delivery Center has issued three batches of notices on the proposed online prices of new products, a total of 31 drugs.

Publicity form for the price information of new varieties approved for listing in Guangdong (the third batch)

CAR-T Therapy Pricing Disclosure

According to data, there are as many as 30 CAR-T therapies entering the clinical stage in China

On the one hand, the domestic CAR-T market is showing increasingly fierce competition, repeated targets, and serious product homogeneity

In foreign countries, some countries have included related CAR-T therapies into the scope of medical insurance

Regarding whether "sky-priced drugs" can be included in the catalog, the National Medical Insurance Administration has stated that some more expensive drugs have passed the preliminary formal review, which only indicates that the drug meets the application requirements after the preliminary review and is eligible to enter the next adjustment link

Innovative medicine and medical insurance negotiations attract attention

  Take Novo Nordisk's smeglutide injection as an example.

  Currently, Eli Lilly's dulaglutide and Novo Nordisk's smeglutide injection are in a period of rapid growth

  Many domestic innovative pharmaceutical companies have also announced their prices

  As a hot drug, ADC drugs have ushered in an outbreak period in the past two years.

  The publicity form of the price information of the new varieties approved for listing in Guangdong (the first batch)